Skip to main content
Medical information Clinical review pending

Gynecological Testing

Preeclampsia Screening Panel Test

The Preeclampsia Screening Panel Test assesses the risk of developing preeclampsia during pregnancy by measuring key biomarkers like PlGF and PAPP-A. Early detection allows for timely management to improve outcomes for mother and baby.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
2 mL (1 mL minimum) serum collected in a Serum Separator Tube (SST).
Results
Reports are typically available the same day if the sample is collected by 9 AM on Tuesday, Thursday, or Saturday. Confirm with the laboratory before booking.
Preparation
A duly filled Pre-eclampsia screening form (Form 13) is mandatory. Confirm with the laboratory before booking.
Test priceKSh 9,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Preeclampsia Screening Panel Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Pregnant women between 10-13 weeks gestation
  • ✓Individuals with a history of preeclampsia in previous pregnancies
  • ✓Pregnant women with pre-existing high blood pressure or diabetes
  • ✓Individuals undergoing fertility treatments like IVF
  • ✓Pregnant women with other risk factors (e.g., smoking)
02

In plain language

What this test helps you understand

This test helps identify pregnant individuals at higher risk of developing preeclampsia, allowing for closer monitoring and potential early intervention to mitigate risks to both mother and baby.
The Preeclampsia Screening Panel Test is a vital tool used during pregnancy to assess the risk of developing preeclampsia. Preeclampsia is a serious condition characterized by high blood pressure and potential damage to organs like the liver and kidneys, posing risks to both the mother and the developing baby. This test is designed for early detection, enabling healthcare providers to implement timely management strategies and monitoring.

This screening panel measures two important biomarkers: Placental Growth Factor (PlGF) and Pregnancy Associated Plasma Protein A (PAPP-A). Levels of these markers can indicate an increased risk for developing preeclampsia, either early or late in pregnancy.

Understanding your risk is crucial for a healthy pregnancy. Discussing the results with your healthcare provider is essential for interpreting them correctly and creating an appropriate care plan.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA duly filled Pre-eclampsia screening form (Form 13) is mandatory. Confirm with the laboratory before booking.
Sample2 mL (1 mL minimum) serum collected in a Serum Separator Tube (SST).
MethodologyImmunoassay method used to measure PlGF and PAPP-A levels in serum. Confirm with the laboratory before booking.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This is a screening test and does not definitively diagnose preeclampsia. Results indicate risk level and should be interpreted by a healthcare professional. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Preeclampsia is a serious pregnancy complication characterized by high blood pressure and signs of damage to other organ systems, often the liver and kidneys.
This screening test is typically recommended for pregnant women between 10 and 13 weeks of gestation.
Placental Growth Factor (PlGF) and Pregnancy Associated Plasma Protein A (PAPP-A) are biomarkers measured in the blood that can help assess the risk of developing preeclampsia.
Your healthcare provider will interpret the results in the context of your medical history. Based on the risk assessment, they may recommend closer monitoring or further management.
No, this is a screening test to assess risk. It does not diagnose preeclampsia. Further evaluation may be needed based on the results and clinical picture.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp